Evidence map›Paper›PMID 28632818›Full record

ArticleThe review of diabetic studies : RDS2017

Benefits of Islet Transplantation as an Alternative to Pancreas Transplantation: Retrospective Study of More Than 10 Ten Years of Experience in a Single Center.

Barbora Voglová, Martina Zahradnická, Peter Girman, Jan Kríž, Zuzana Berková, Tomáš Koblas, Ema Vávrová, Lenka Németová, Lucie Kosinová, David Habart and 11 more

Open access · diamondAbstract read
In one paragraph

Article in The review of diabetic studies : RDS, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 14 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Barbora VoglováDepartment of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Martina ZahradnickáDepartment of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Peter GirmanDepartment of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Jan KrížDepartment of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Zuzana BerkováDepartment of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Tomáš KoblasDepartment of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Ema VávrováDepartment of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Lenka NémetováDepartment of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Lucie KosinováDepartment of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
David HabartDepartment of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Eva FábryováDepartment of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Eva DovolilováDepartment of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Ivan LeontovycDepartment of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Tomáš NeškudlaDepartment of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Jan PeregrinDepartment of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Jozef KovácDepartment of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Kvetoslav LipárDepartment of Transplant Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Matej KocíkDepartment of Transplant Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Tomáš MaradaDepartment of Transplant Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Jirí SvobodaDepartment of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
František SaudekDepartment of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Institute of Clinical and Experimental Medicine · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreas transplantation (PTx) represents the method of choice in type 1 diabetic patients with conservatively intractable hypoglycemia unawareness syndrome. In 2005, the Institute for Clinical and Experimental Medicine (IKEM) launched a program to investigate the safety potential of islet transplantation (ITx) in comparison to PTx.

aimThis study aims to compare the results of PTx and ITx regarding severe hypoglycemia elimination, metabolic control, and complication rate.

methodsWe analyzed the results of 30 patients undergoing ITx and 49 patients treated with PTx. All patients were C-peptide-negative and suffered from hypoglycemia unawareness syndrome. Patients in the ITx group received a mean number of 12,349 (6,387-15,331) IEQ/kg/person administered percutaneously into the portal vein under local anesthesia and radiological control. The islet number was reached by 1-3 applications, as needed. In both groups, we evaluated glycated hemoglobin, insulin dose, fasting and stimulated C-peptide, frequency of severe hypoglycemia, and complications. We used the Mann Whitney test, Wilcoxon signed-rank test, and paired t-test for analysis. We also individually assessed the ITx outcomes for each patient according to recently suggested criteria established at the EPITA meeting in Igls.

resultsMost of the recipients showed a significant improvement in metabolic control one and two years after ITx, with a significant decrease in HbA1c, significant elevation of fasting and stimulated C-peptide, and a markedly significant reduction in insulin dose and the frequency of severe hypoglycemia. Seventeen percent of ITx recipients were temporarily insulin-independent. The results in the PTx group were comparable to those in the ITx group, with 73% graft survival and insulin independence in year 1, 68% 2 years and 55% 5 years after transplantation. There was a higher rate of complications related to the procedure in the PTx group. Severe hypoglycemia was eliminated in the majority of both ITx and PTx recipients.

conclusionThis report proves the successful initiation of pancreatic islet transplantation in a center with a well-established PTx program. ITx has been shown to be the method of choice for hypoglycemia unawareness syndrome, and may be considered for application in clinical practice if conservative options are exhausted.

Indexed as

Islets of Langerhans TransplantationPancreas TransplantationAdultBlood GlucoseChoice BehaviorC-PeptideDiabetes Mellitus, Type 1FemaleFollow-Up StudiesGraft SurvivalHumansHypoglycemiaMaleMiddle AgedRetrospective StudiesRisk AssessmentBlood GlucoseC-Peptide

Identifiers

PMID28632818
PMCPMC6115003
OpenAlexW2991167058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.